NASDAQ: OPTOpthea Ltd Stock
$3.59-0.23 (-6.02%)
Updated Jan 15, 2025
OPT Price
$3.59
Fair Value Price
$0.23
Market Cap
$489.80M
52 Week Low
$1.79
52 Week High
$5.45
P/E
-1.3x
P/B
-6.46x
P/S
430.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$261.86k
Earnings
-$220.24M
Gross Margin
100%
Operating Margin
-76,144.51%
Profit Margin
-84,107.1%
Debt to Equity
-3.49
Operating Cash Flow
-$161M
Beta
0.35
Next Earnings
Feb 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A
OPT Overview
Opthea Limited is develing therapies that treat highly prevalent and progressive retinal eye diseases (wet age-related macular degeneration and diabetic macular edema). Its lead product candidate, OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients. Opthea was incorporated in 1984 and is headquartered in South Yarra, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OPT's potential to beat the market
- OPT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OPT
RankedUnranked of 555
RankedUnranked of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.01 | A | |
| $123.24 | A | |
| $3.07 | A |
Be the first to know about important OPT news, forecast changes, insider trades & much more!
OPT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OPT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OPT ($3.59) is overvalued by 1,463.2% relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OPT ($3.59) is not significantly undervalued (1,463.2%) relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OPT due diligence checks available for Premium users.
Valuation
OPT fair value
Fair Value of OPT stock based on Discounted Cash Flow (DCF)
Price
$3.59
Fair Value
$0.23
Overvalued by
1,463.20%
OPT ($3.59) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OPT ($3.59) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OPT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.3x
Industry
-122.62x
Market
30.62x
OPT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.46x
Industry
4.83x
OPT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
OPT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OPT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$188.8M
Liabilities
$264.6M
Debt to equity
-3.49
OPT's short-term assets ($188.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OPT's long-term liabilities ($200.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OPT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OPT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
OPT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OPT vs Biotech Stocks
Opthea Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.